Value of procalcitonin and presepsin in the diagnosis and severity stratification of sepsis and septic shock

doi:10.5847/wjem.j.1920-8642.2024.028

World Journal of Emergency Medicine ›› 2024, Vol. 15 ›› Issue (2): 135-138.doi: 10.5847/wjem.j.1920-8642.2024.028

• Research Letter • Previous Articles Next Articles

Value of procalcitonin and presepsin in the diagnosis and severity stratification of sepsis and septic shock

Enfeng Ren¹, Hongli Xiao¹, Guoxing Wang¹, Yongzhen Zhao², Han Yu², Chunsheng Li¹()

¹Department of Emergency Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
²Department of Emergency Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100050, China

Received:2023-06-06 Accepted:2023-10-26 Online:2024-03-11 Published:2024-03-01
Contact: Chunsheng Li, Email: lcscyyy@163.com

Abstract

Enfeng Ren, Hongli Xiao, Guoxing Wang, Yongzhen Zhao, Han Yu, Chunsheng Li. Value of procalcitonin and presepsin in the diagnosis and severity stratification of sepsis and septic shock[J]. World Journal of Emergency Medicine, 2024, 15(2): 135-138.

Figures/Tables 3

Table 1.

Figure 1.

Figure 2.

References 15

1	Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315(8): 801-10. doi: 10.1001/jama.2016.0287 pmid: 26903338
2	Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395(10219): 200-11. doi: S0140-6736(19)32989-7 pmid: 31954465
3	Wang W, Liu CF. Sepsis heterogeneity. World J Pediatr. 2023; 19(10):919-27. doi: 10.1007/s12519-023-00689-8 pmid: 36735197
4	Ruan L, Chen GY, Liu Z, Zhao Y, Xu GY, Li SF, et al. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review. Crit Care. 2018; 22(1): 316. doi: 10.1186/s13054-018-2236-1
5	Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit Care. 2013; 17(5): R244. doi: 10.1186/cc13070
6	Xiao HL, Wang GX, Wang Y, Tan ZM, Sun XL, Zhou J, et al. Potential value of presepsin guidance in shortening antibiotic therapy in septic patients: a multicenter, prospective cohort trial. Shock. 2022; 57(1): 63-71. doi: 10.1097/SHK.0000000000001870
7	Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017; 377(6): 562-72. doi: 10.1056/NEJMra1608077
8	Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012; 380(9843): 756-66. doi: 10.1016/S0140-6736(11)61454-2 pmid: 22617274
9	Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13(5): 426-35. doi: 10.1016/S1473-3099(12)70323-7 pmid: 23375419
10	Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a systematic review. Crit Care. 2013; 17(6):1-8.
11	Schuetz P, Maurer P, Punjabi V, Desai AM, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care. 2013; 17(3): R115.
12	Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014; 34(4): 263-73. doi: 10.3343/alm.2014.34.4.263 pmid: 24982830
13	Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004; 279(47): 48487-90. doi: 10.1074/jbc.R400025200 pmid: 15337754
14	Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, IL-6, or LBP. Crit Care Res Pract. 2011; 2011: 594645.
15	Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015; 41(1): 12-20. doi: 10.1007/s00134-014-3514-2 pmid: 25319385

Variables	Total (n=2,255)	Sepsis (n=1,970)	Septic shock (n=285)	P-value
Age, years	72.0 (60.0-80.0)	72.0 (60.0-80.0)	72.0 (67.0-79.0)	0.445
Male	1,338 (59.3)	1,183 (60.1)	155 (54.4)	0.079
Chronic heart disease	1-069 (47.4)	905 (45.9)	164 (57.5)	<0.001
COPD	482 (21.4)	432 (21.9)	27 (17.4)	0.107
CKD	158 (7.0)	144 (7.3)	14 (4.9)	0.175
CRP, mg/L	66.0 (50.0-82.0)	67.0 (53.0-82.0)	61.0 (35.0-87.0)	0.026
PCT, µg/L	2.0 (0.0-8.5)	2.0 (0.0-7.0)	11.0 (2.0-25.0)	<0.001
Presepsin, pg/mL	1,119.0 (664.5-1-817.0)	1,070.0 (646.0-1,710.5)	1,841.0 (870.0-3,124.0)	<0.001
PaO₂/FiO₂, mmHg	258.0 (204.0-307.0)	259.0 (208.0-306.0)	243.0 (179.0-316.0)	0.038
Lactate, mmol/L	2.0 (1.0-3.0)	2.0 (1.0-3.0)	3.0 (2.0-5.0)	<0.001
ISTH	2.0 (1.0-2.0)	2.0 (1.0-2.0)	2.0 (1.0-2.0)	0.674
APACHE II	16.0 (10.0-22.0)	15.0 (10.0-21.0)	23.0 (16.0-29.0)	<0.001
SOFA	5.0 (3.0-9.0)	4.0 (3.0-8.0)	13.0 (8.0-18.0)	<0.001
MEDS	11.0 (8.0-16.0)	11.0 (8.0-14.0)	18.0 (13.0-21.0)	<0.001
SAPS II	35.0 (28.0-43.0)	33.0 (27.0-41.0)	49.0 (40.0-59.0)	<0.001
ARDS	1,801 (79.9)	1,590 (80.7)	211 (74.0)	<0.001
AKI	952 (42.2)	736 (37.4)	216 (75.8)	<0.001
Hospitalization cost, RMB yuan	63,880.0 (38,216.5-99,073.0)	61,674.0 (36,979.0-97,029.0)	80,104.0 (49,635.0-11,2308.0)	<0.001
28-day mortality	757 (33.6)	589 (29.9)	168 (58.9)	<0.001

Value of procalcitonin and presepsin in the diagnosis and severity stratification of sepsis and septic shock

RichHTML

PDF (PC)

Supplement

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 15

Related Articles 0

Recommended Articles

Comments